KR20220100992A - 브루톤 티로신 키나제 억제제의 투여 - Google Patents
브루톤 티로신 키나제 억제제의 투여 Download PDFInfo
- Publication number
- KR20220100992A KR20220100992A KR1020227022407A KR20227022407A KR20220100992A KR 20220100992 A KR20220100992 A KR 20220100992A KR 1020227022407 A KR1020227022407 A KR 1020227022407A KR 20227022407 A KR20227022407 A KR 20227022407A KR 20220100992 A KR20220100992 A KR 20220100992A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- cycle
- days
- administered
- btk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title description 507
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 710
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 475
- 201000011510 cancer Diseases 0.000 claims abstract description 474
- 229940124291 BTK inhibitor Drugs 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 23
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 711
- 238000011319 anticancer therapy Methods 0.000 claims description 134
- 238000011282 treatment Methods 0.000 claims description 132
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 6
- 201000004085 CLL/SLL Diseases 0.000 claims description 5
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims description 5
- FWZAWAUZXYCBKZ-NSHDSACASA-N 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide Chemical compound COc1ccc(F)cc1C(=O)NCc1ccc(cc1)-c1nn([C@@H](C)C(F)(F)F)c(N)c1C(N)=O FWZAWAUZXYCBKZ-NSHDSACASA-N 0.000 claims description 3
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- -1 5-fluoro-2-methoxybenzamido Chemical group 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 description 1164
- 229960004641 rituximab Drugs 0.000 description 830
- 239000012664 BCL-2-inhibitor Substances 0.000 description 643
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 640
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 506
- 230000001404 mediated effect Effects 0.000 description 418
- 229960001183 venetoclax Drugs 0.000 description 366
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 366
- 231100000402 unacceptable toxicity Toxicity 0.000 description 135
- 210000003719 b-lymphocyte Anatomy 0.000 description 115
- 230000004083 survival effect Effects 0.000 description 114
- 230000035755 proliferation Effects 0.000 description 112
- 230000005764 inhibitory process Effects 0.000 description 111
- 229960003347 obinutuzumab Drugs 0.000 description 92
- 239000003814 drug Substances 0.000 description 88
- 238000004519 manufacturing process Methods 0.000 description 87
- 230000002401 inhibitory effect Effects 0.000 description 40
- 229940124650 anti-cancer therapies Drugs 0.000 description 29
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 11
- 229960001507 ibrutinib Drugs 0.000 description 11
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 7
- 208000017760 chronic graft versus host disease Diseases 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 206010003658 Atrial Fibrillation Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 229940045793 B-cell lymphoma-2 inhibitor Drugs 0.000 description 3
- 206010033661 Pancytopenia Diseases 0.000 description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000024389 cytopenia Diseases 0.000 description 3
- 201000003444 follicular lymphoma Diseases 0.000 description 3
- 208000034656 Contusions Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229950009821 acalabrutinib Drugs 0.000 description 2
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 235000006810 Caesalpinia ciliata Nutrition 0.000 description 1
- 241000059739 Caesalpinia ciliata Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- SRSYFANOKMRZEY-UHFFFAOYSA-N FC(C(C)N1N=CC(=C1)C(=O)N)(F)F Chemical compound FC(C(C)N1N=CC(=C1)C(=O)N)(F)F SRSYFANOKMRZEY-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000025316 Richter syndrome Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020237028538A KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944674P | 2019-12-06 | 2019-12-06 | |
| US62/944,674 | 2019-12-06 | ||
| US202063077996P | 2020-09-14 | 2020-09-14 | |
| US63/077,996 | 2020-09-14 | ||
| US202063109698P | 2020-11-04 | 2020-11-04 | |
| US63/109,698 | 2020-11-04 | ||
| PCT/US2020/063089 WO2021113497A1 (en) | 2019-12-06 | 2020-12-03 | Dosing of a bruton's tyrosine kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237028538A Division KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220100992A true KR20220100992A (ko) | 2022-07-18 |
Family
ID=73854977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227022407A Ceased KR20220100992A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
| KR1020237028538A Pending KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237028538A Pending KR20230127372A (ko) | 2019-12-06 | 2020-12-03 | 브루톤 티로신 키나제 억제제의 투여 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230041515A1 (enExample) |
| EP (1) | EP4069219A1 (enExample) |
| JP (3) | JP7142173B2 (enExample) |
| KR (2) | KR20220100992A (enExample) |
| CN (1) | CN115175677A (enExample) |
| AU (2) | AU2020397034B2 (enExample) |
| BR (1) | BR112022009716A2 (enExample) |
| IL (1) | IL292882A (enExample) |
| MX (1) | MX2022006631A (enExample) |
| WO (1) | WO2021113497A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| KR20220100992A (ko) * | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA55064A (fr) * | 2015-12-16 | 2021-09-29 | Loxo Oncology Inc | Composés utilisés comme inhibiteurs de kinase |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| KR102429704B1 (ko) | 2016-08-05 | 2022-08-04 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물 |
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| CN110546151B (zh) | 2017-04-18 | 2023-04-28 | 重庆复创医药研究有限公司 | 凋亡诱导剂 |
| JP2020528061A (ja) | 2017-07-26 | 2020-09-17 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法 |
| SG11202005985PA (en) | 2018-01-10 | 2020-07-29 | Recurium Ip Holdings Llc | Benzamide compounds |
| FI3788042T3 (fi) | 2018-04-29 | 2025-04-07 | Beigene Switzerland Gmbh | Bcl-2-inhibiittoreita |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| KR20220100992A (ko) * | 2019-12-06 | 2022-07-18 | 록쏘 온콜로지, 인코포레이티드 | 브루톤 티로신 키나제 억제제의 투여 |
-
2020
- 2020-12-03 KR KR1020227022407A patent/KR20220100992A/ko not_active Ceased
- 2020-12-03 BR BR112022009716A patent/BR112022009716A2/pt unknown
- 2020-12-03 EP EP20825385.6A patent/EP4069219A1/en active Pending
- 2020-12-03 JP JP2021557408A patent/JP7142173B2/ja active Active
- 2020-12-03 AU AU2020397034A patent/AU2020397034B2/en active Active
- 2020-12-03 IL IL292882A patent/IL292882A/en unknown
- 2020-12-03 MX MX2022006631A patent/MX2022006631A/es unknown
- 2020-12-03 WO PCT/US2020/063089 patent/WO2021113497A1/en not_active Ceased
- 2020-12-03 US US17/782,758 patent/US20230041515A1/en active Pending
- 2020-12-03 CN CN202080095816.0A patent/CN115175677A/zh active Pending
- 2020-12-03 KR KR1020237028538A patent/KR20230127372A/ko active Pending
-
2022
- 2022-09-12 JP JP2022144243A patent/JP7654604B2/ja active Active
-
2024
- 2024-02-26 AU AU2024201263A patent/AU2024201263B2/en active Active
-
2025
- 2025-03-19 JP JP2025044178A patent/JP2025098099A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ788615A (en) | 2024-10-25 |
| KR20230127372A (ko) | 2023-08-31 |
| MX2022006631A (es) | 2022-09-07 |
| AU2024201263A1 (en) | 2024-03-14 |
| BR112022009716A2 (pt) | 2022-08-09 |
| JP2022518974A (ja) | 2022-03-17 |
| US20230041515A1 (en) | 2023-02-09 |
| AU2020397034A1 (en) | 2022-07-21 |
| JP2025098099A (ja) | 2025-07-01 |
| CA3160417A1 (en) | 2021-06-10 |
| JP2022177119A (ja) | 2022-11-30 |
| WO2021113497A1 (en) | 2021-06-10 |
| CN115175677A (zh) | 2022-10-11 |
| AU2020397034B2 (en) | 2023-12-07 |
| JP7654604B2 (ja) | 2025-04-01 |
| AU2024201263B2 (en) | 2025-05-01 |
| EP4069219A1 (en) | 2022-10-12 |
| JP7142173B2 (ja) | 2022-09-26 |
| IL292882A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3458091B1 (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| US20170306050A1 (en) | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases | |
| US20230107195A1 (en) | Treatment of cancer with smg1-inhibitors | |
| CN110325191A (zh) | 以较少的副作用治疗egfr-驱动的癌症 | |
| UA125216C2 (uk) | Комбінована терапія | |
| JP2022044767A (ja) | 癌を処置する方法 | |
| AU2024201263B2 (en) | Dosing of a Bruton's Tyrosine Kinase inhibitor | |
| CA2853498A1 (en) | Methods of treating a bruton's tyrosine kinase disease or disorder | |
| JP2016522247A (ja) | 組合せ医薬 | |
| CA3107023A1 (en) | Ep4 inhibitors and synthesis thereof | |
| KR20210106483A (ko) | Mdm2 억제제를 위한 확장된 저용량 요법 | |
| CN114246864B (zh) | Csf1r激酶抑制剂及其用途 | |
| WO2021207598A1 (en) | Combination treatment with an agonist of p53 and a second therapeutic agent | |
| IL258574B2 (en) | Uses of myostatin antagonists, combinations containing them and their uses | |
| CA3160417C (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| JP5393691B2 (ja) | 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬（ＴｐｏＲＡ） | |
| CN101969947B (zh) | 使用诸如呋咯地辛的pnp抑制剂与烷化剂或抗cd20剂的组合治疗血液学癌症的方法 | |
| EA046722B1 (ru) | Введение доз ингибитора тирозинкиназы брутона | |
| NZ788615A9 (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| EP4504202A1 (en) | Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer | |
| AU2012321091B2 (en) | Methods of treating a Bruton's Tyrosine Kinase disease or disorder | |
| HK40004756A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| HK40004756B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0105 | International application |
Patent event date: 20220630 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20220630 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20220630 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230119 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230527 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230119 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20230822 |